Innovative Launch of Gobivaz®: A New Hope for Patients
Alvotech (NASDAQ: ALVO), a biotech pioneer dedicated to developing biosimilar medicines, and Advanz Pharma, a UK-based pharmaceutical leader in specialty therapies, recently celebrated a significant achievement. The European Commission (EC) granted marketing authorization for Gobivaz®, marking it as the first biosimilar to Simponi® (golimumab) approved in the European Economic Area (EEA).
Expanded Treatment Options for Immune-Mediated Diseases
The approved formulations of Gobivaz® include 50 mg/0.5 mL and 100 mg/mL options, available in pre-filled syringes equipped with a passive needle safety guard and autoinjectors. These products are intended to treat diverse conditions such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, and juvenile idiopathic arthritis in children aged two and older when used alongside methotrexate. The EC’s decision builds upon a favorable recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
A Commitment to Accessibility and Quality
Robert Wessman, Chairman and CEO of Alvotech, expressed his enthusiasm about the EC approval, highlighting that this milestone reinforces their partnership with Advanz Pharma. He emphasized their dedication to increasing access to high-quality biologic therapies for individuals living with immune-mediated diseases. Steffen Wagner, CEO of Advanz Pharma, echoed this sentiment, affirming the importance of expanding treatment options across Europe through Gobivaz®.
Collaboration Details and Clinical Evidence
Under their collaboration, Alvotech oversees the development and supply of Gobivaz®, while Advanz Pharma retains exclusive commercialization rights within the EEA and the UK. The EC's authorization was granted after a comprehensive review of clinical data. Alvotech previously shared positive results from a confirmatory clinical trial that evaluated the efficacy, safety, and immunogenicity of its biosimilar candidate, AVT05, compared to the reference product Simponi® in patients with moderate to severe rheumatoid arthritis.
Further Clinical Outcomes
In another notable study, Alvotech reported successful pharmacokinetic results, comparing AVT05 with Simponi® in healthy adults, demonstrating favorable safety and tolerability profiles.
Understanding Gobivaz® (AVT05)
Gobivaz® (golimumab) has already been approved in Japan and now secures its presence in the European market. As a monoclonal antibody, it inhibits tumor necrosis factor alpha (TNF alpha), a contributor to chronic inflammatory conditions like rheumatoid arthritis. A dedicated focus on this molecule exemplifies Alvotech’s strategic efforts to address unmet needs in the biosimilar landscape.
About Alvotech: Driving Change in Biologics
Founded by Robert Wessman, Alvotech aims to lead the biosimilar sector by creating high-quality, cost-effective solutions for patients across the globe. Their current development pipeline features eight distinct candidates targeting autoimmune disorders, cancer, and other major health challenges.
About Advanz Pharma: A Global Leader in Specialty Medicines
With an ambition to enhance patient lives through the provision of specialty and rare disease medications, Advanz Pharma operates in over 90 countries and features a strategic global distribution network. Their diverse product portfolio underscores their commitment to therapeutic innovation in complex healthcare areas.
Frequently Asked Questions
What is Gobivaz®?
Gobivaz® is a biosimilar medication to Simponi® (golimumab), approved for various immune-mediated diseases across Europe.
How does Gobivaz® work?
As a monoclonal antibody, Gobivaz® inhibits TNF alpha, which plays a significant role in chronic inflammation, particularly in conditions like rheumatoid arthritis.
What are the key approvals received for Gobivaz®?
Gobivaz® received approval from the European Commission for multiple formulations suitable for treating rheumatoid arthritis and related conditions.
Why is Gobivaz® significant?
This product is notable as it represents the first biosimilar to Simponi® approved in the European market, promoting access to essential medicines.
Who is behind the development of Gobivaz®?
Gobivaz® is developed by Alvotech in collaboration with Advanz Pharma, which handles registration and commercialization in the EEA and the UK.
